JPRN-jRCT2080224912已完成3 期
A Phase 3, randomized, placebo-controlled, double blind study of KW-3357 in patients with early onset severe preeclampsia
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 180
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 18age old 至 ot applicable（—）
- 性别
- Female
入选标准
- •1) Patients who gave written consent to participate in the clinical trial by their own free will.
- •2) Patients aged 18 years or older at the time of obtaining informed consent
- •3) Patients with early-onset PE * 24 weeks 0 to 31 weeks 6 days of gestation at the time of enrollment
- •*: Determine the definition of gestational age based on the Guidelines for Obstetrics and Gynecology, Obstetrics, 2020
- •4) Patients diagnosed with severe PE*
- •*: Follow the diagnostic criteria of the Japan Society for the Study of Hypertension in Pregnancy
- •5) Patients with AT activity of 100% or less in the preliminary test
排除标准
- •1) Patients who are judged to require immediate delivery*
- •* Best Practice Guide 2015 for Care and Treatment of Hypertension in Pregnancy Requirements for Considering Pregnancy Termination Regardless of Pregnancy Weeks in Pregnancy-induced Hypertension Syndrome Case will be consulted for judgment.
- •2) Patients with right hypochondralgia or epigastralgia
- •3) Patients with HELLP syndromes
- •4) Patients with pulmonary edema
- •5) Patients with severe pleural effusion, severe ascites, or serous retinal detachment
- •6) Patients with central nervous system disorders (eclampsia, stroke) or visual disorders (cortical blindness)
- •7) Patients with severe headache or urge eclampsia
- •8) Patients with abruptio placentae
- •9) Suspected patients with 8 or more obstetric DIC scores
- •10) Patients with a definitive diagnosis of congenital AT deficiency
- •11) Patients with diseases or symptoms other than the primary disease requiring immediate delivery
- •12) Patients on ongoing treatment with nonsteroidal anti-inflammatory drugs (NSAIDs, e.g., aspirin) or who require NSAIDs use during the course of the study.
- •13) Patients who have received the following drugs within 72 hours before administration of the investigational product, etc., or who require administration of the following drugs during the study period (from the start of administration of the investigational product, etc., until the date of termination of gestation); heparin, low-molecular-weight heparin (e.g., enoxaparin or dalteparin), fondaparinux, antiplatelet drugs (e.g., clopidogrel, prasugrel, aspirin), direct thrombin inhibitors (e.g., dabigatran), or anticoagulants (e.g., AT preparations).
- •14) Patients with a current or past history of serious drug allergy
- •15) Patients with a history or complication of drug dependence or alcoholism
- •16) Patients with hypersensitivity to AT preparations
- •17) Patients who are pregnant with a fetus with a chromosomal abnormality or a fetus suspected of having a serious malformation syndrome
- •18) Patients with multiple pregnancies
- •19) Patients with a history or complication of antiphospholipid antibody syndrome
- •20) Patients with diabetes complicated pregnancy or obvious diabetes mellitus
- •21) Patients with uncontrollable or significant complications, including the following
- •- Clinically significant cardiovascular diseases, etc. (New York Heart Association cardiac function classifications Class III or higher)
- •- Serious hepatic disease
- •- Severe renal disease
- •- Pneumonia, interstitial lung disease or other severe respiratory disease
- •- Blood disorders such as idiopathic thrombocytopenic purpura
- •- Psycho-central nervous system disorders that may affect informed consent
- •- Endocrine disorders such as hyperthyroidism
- •- Autoimmune diseases such as systemic lupus erythematosus
- •22) Patients with active malignancy or patients with a history of onset or treatment of malignancy within 5 years before pregnancy (excluding excised or surgically cured basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or ductal carcinoma of the breast, and excluding cervical intraepithelial neoplasia regardless of excised or surgically cured or not)
- •23) Patients with active infections (e.g., toxoplasma infection, genital chlamydia, genital herpes, cytomegalovirus infection)
- •24) Patients with a positive history for HIV antibody. Patients with a positive history for HBs antigen and HCV antibody and with active infection presenting with hepatitis symptoms.
- •25) Patients with
研究者
相似试验
进行中（未招募）
不适用
A Phase III randomized, placebo controlled, double blind trial of Sorafenib plus Erlotinib vs. Sorafenib plus placebo as First Line systemic treatment for Hepatocellular Carcinoma (HCC). - SEARCHTo evaluate the clinical benefit of sorafenib 400 mg twice daily and erlotibib 150 mg once a day in subjects with unresectable advanced or metastatic Child-Pugh A HCCMedDRA version: 9.1Level: LLTClassification code 10019828MedDRA version: 9.1Level: LLTClassification code 10019829EUCTR2008-006021-14-ITBayer HealthCare AG700
已完成
3 期
A phase 3, randomized, placebo-controlled, double-blind study of vimseltinib to assess the efficacy and safety in patients with tenosynovial giant cell tumor (MOTION)Advanced tumorsrare tumor arising from the jointsTenosynovial Giant Cell Tumor1001336110041294NL-OMON56439Deciphera Pharmaceuticals, LLC20
招募中
3 期
A phase 3 study of TAS-205 in patients with Duchenne muscular dystrophyDuchenne Muscular DystrophyDMDJPRN-jRCT2041200055Takeda Shin'ichi100
招募中
3 期
A phase 3, randomized, placebo-controlled, double-blinded, multicenter study to evaluate the efficacy and safety of pegcetacoplan in patients with C3 glomerulopathy or immune-complex membranoproliferative glomerulonephritisglomerulus diseaseskidney diseases10029149NL-OMON55956Apellis Pharmaceuticals, Inc5
进行中（未招募）
1 期
A clinical trial to determine the efficacy and safety of Presendin in idiopathic intracranial hypertensioMedDRA version: 23.1Level: PTClassification code 10078904Term: Idiopathic intracranial hypertensionSystem Organ Class: 10029205 - Nervous system disordersIdiopathic intracranial hypertensionEUCTR2021-006664-24-FRInvex Therapeutics Ltd.240